CMG Pharmaceutical Co.,Ltd. – Trademark Portfolio

Entity Type: 03

CMG Pharmaceutical Co.,Ltd. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. Currently, 1 trademark is registered and 3 are pending. Notable registered marks include ARINGAGE. The owner is based in Gangnam-gu, Seoul.

14, Dosan-daero 66-gil

Gangnam-gu, Seoul , KR

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MEZOFY
MEZOFY
Pending 2025
RIOFY
RIOFY
Pending 2025
ARIQOZY
ARIQOZY
Pending 2025
DEPIPZO
DEPIPZO
Cancelled 2018
ORPIPSO
ORPIPSO
Cancelled 2018
ARINGAGE
ARINGAGE
Registered 2018

Trademark Classifications

CMG Pharmaceutical Co.,Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does CMG Pharmaceutical Co.,Ltd. have?

CMG Pharmaceutical Co.,Ltd. has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 pending, 2 cancelled.

What trademark classes does CMG Pharmaceutical Co.,Ltd. file in?

CMG Pharmaceutical Co.,Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CMG Pharmaceutical Co.,Ltd.'s most well-known trademarks?

CMG Pharmaceutical Co.,Ltd.'s registered trademark portfolio includes well-known marks such as ARINGAGE. These are among 1 currently registered trademark in the portfolio.

What is CMG Pharmaceutical Co.,Ltd.'s trademark registration success rate?

CMG Pharmaceutical Co.,Ltd. has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 3 applications are pending review.